Abbott Moves to Expand Medical Device Production at FTZ 39

FTZ News:  In the industrial corridors of Irving, just west of Dallas/Fort Worth International Airport, Abbott Laboratories has asked federal regulators for permission to expand production of diagnostic medical devices inside Foreign-Trade Zone 39. The formal notification, received by the Foreign-Trade Zones Board on August 3 and published three days later, is a quiet but revealing step in how one of America’s largest healthcare companies continues to manage costs and supply-chain risk.

The Specific Ask

Abbott wants authority to manufacture a long list of components and finished instruments under FTZ procedures. The products range from plastic fitting kits, sensor assemblies, and cooler systems with heat exchangers to barcode scanners, pipettor mechanisms, printed circuit boards, and complete diagnostic analyzers. Duty rates on these items, if entered outside an FTZ, would range from zero to 5.8 percent. Inside the zone, those duties can be deferred, reduced, or eliminated on re-exports.

Why FTZ 39 Matters

Foreign-Trade Zone 39, run by the Dallas/Fort Worth International Airport Board since 1978, is one of the more active zones in the country. In 2024 it received more than $21.7 billion in merchandise. Nationally, U.S. FTZs handled roughly $964 billion in receipts that year, supported about 543,000 jobs, and generated approximately $133.5 billion in exports. Production activity accounted for roughly 61 percent of all merchandise received—evidence that these zones function more as manufacturing platforms than simple storage sites.

Abbott’s North Texas Footprint

Abbott already employs around 2,000 people across the Dallas-Fort Worth region. The Irving facility sits inside a logistics ecosystem that has become increasingly important for medical technology. By bringing foreign-status sensors, specialized plastics, electronic modules, and precision metal parts into the zone, the company can assemble complex diagnostic systems with greater flexibility on duty treatment. In an industry where a single analyzer can contain hundreds of globally sourced components, even modest duty savings add up.

Timing and Context

The request comes as medical-device makers continue to navigate elevated input costs and shifting trade rules. Public comments on the notification close September 15. Historically, applications of this type in the diagnostics sector face little opposition. If approved, the authorization will allow Abbott to keep more sophisticated assembly work in North Texas while retaining the option to re-export finished instruments under more favorable terms.

Broader Signal

The filing is not dramatic. It does not announce hundreds of new jobs or a major plant expansion. What it does show is the continued usefulness of the FTZ program for high-value, precision manufacturing. In an environment where reliability and regulatory compliance matter as much as unit cost, companies still reach for every available tool to keep advanced production close to the markets they serve. Abbott’s move in Irving is one more data point in that quiet recalibration./.